Zheng-Wei Peng

Abstract B046: Pseudo-irreversible, pan-KRAS inhibitor BH-501284 achieves prolonged inhibition of KRAS signaling leading to deep and durable antitumor efficacy in mouse tumor models

KRAS is a frequently mutated oncogene in pancreatic cancer. Trial success with Switch-II covalent KRAS G12C inhibitors and panRAS tricomplex inhibitors validates KRAS mutations as targetable oncogenic drivers. Yet the development of non-covalent KRAS inhibitors has remained challenging due to the shallow Switch-I...